You are here

Thiazolidinediones and Cardiovascular Events in High-Risk Patients with Type-2 Diabetes Mellitus

A Comparison with Other Oral Antidiabetic Agents
Fadia T. Shaya, PhD, MPH; Zhiqiang Lu, BSPharm, PhD Candidate; Kyongsei Sohn, PhD, MBA; and Matthew R. Weir, MD
PDF version: 
In a study of a largely minority population of diabetic Medicaid recipients, rosi­- glitazone (Avandia) was linked to an increase in myocardial infarction and stroke, whereas pioglitazone (Actos) and thiazolidinediones as a class did not show such an association.